EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
2 days ago · The $16.5 billion deal, announced in February, underscores Novo Nordisk's drive to boost output of Wegovy, a once-weekly injection. After the deal closes, Novo Holdings will sell three of Catalent ...
EU regulators seek info from rivals, customers in Catalent sale to Novo …
1 day ago · Catalent and Novo Nordisk Foundation received a request for more information from the Federal Trade Commission in May on their planned deal. In February, Catalent agreed to be acquired by Novo ...
EU Regulators Quiz Novo Nordisk, Catalent Rivals on $16.5 …
2 days ago · The $16.5 billion deal, announced in February, underscores Novo Nordisk's drive to boost output of Wegovy, a once-weekly injection. After the deal closes, Novo Holdings will sell three of Catalent ...
Catalent's Open Letter to Customers Regarding Novo Holdings
Oct 21, 2024 · Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings. Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close. Alessandro Maselli to Remain President and CEO of Catalent Post-Close.
Novo Holdings to Acquire Catalent
Feb 5, 2024 · Catalent and Novo Holdings have entered into a merger agreement in an all-cash transaction that values Catalent at $16.5 billion. Catalent Stockholders to Receive $63.50 Per Share in Cash, Representing a 47.5% Premium to the 60-day Volume-Weighted Average Price as of February 2, 2024
Novo Nordisk tackles supply issues with $11bn Catalent deal
3 days ago · Novo Nordisk is buying three Catalent facilities for $11bn in a bid to resolve supply issues holding back growth of Ozempic for diabetes and obesity therapy Wegovy.
Catalent and Novo Holdings
Feb 5, 2024 · Catalent’s 50+ global sites. Post-close, Novo Holdings intends to sell three of Catalent’s 50+ sites located in Anagni, Italy; Bloomington, Indiana USA; and Brussels, Belgium and related assets to Novo Nordisk. Novo Nordisk operates separately from Novo Holdings. “Catalent will remain a leading global service provider to the biotech ...
News Details - Novo Nordisk
Feb 5, 2024 · Novo Nordisk has agreed to acquire the three sites from a subsidiary of Novo Holdings, as part of a transaction where the subsidiary of Novo Holdings has agreed to acquire Catalent (NYSE: CTLT) through a merger.
Novo Nordisk's parent to buy Catalent for $16.5 bln to ...
Feb 5 (Reuters) - Novo Nordisk (NOVOb.CO) notched a win on Monday in its race to boost output of its popular obesity drug Wegovy, with its parent company announcing it was buying Catalent (CTLT.N),...
Novo Nordisk strikes $11bn deal to expand production of weight …
Feb 5, 2024 · The plants Novo Nordisk is acquiring from Catalent, which specialises in “fill-finish” operations, or the final stage of manufacturing drugs, are in Indiana, Brussels and Anagni, Italy. Two...